

PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q3, 2013/14)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target. 11 patients recruited within agreed date. Long term follow up since July 2011.
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease	10	01/01/2014	Open	Y	Study delivered to time and target. 12 patients recruited within agreed date.
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target. 13 patients recruited within agreed date. Long term follow up since July 2011.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study delivered to time and target. 33 patients recruited within agreed date.
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β-1a) in patients with Relapsing-remitting Multiple Sclerosis	6	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target. 7 patients recruited within agreed date.
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to time and target. Study has been in follow up since 2008.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)	5	15/06/2008	Closed - In Follow Up	Y	Study delivered to time and target. Study in follow up since 2011.
06/MRE06/65	Peri-operative chemotherapy in patients with resectable colorectal liver metastases - does the addition of an anti-EGF receptor antibody improve progression free survival? A prospective randomised open label trial of oxaliplatin/fluoropyrima	2	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target. Study in follow up since 2011.
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	Y	Study delivered to time and target. Target reached 12 months ahead of date agreed.
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC) NV22688	2	No Date Agreed With Sponsor	Open	Y	Study delivered to time and target.
10/H0504/57	A Randomised Double-blind Phase IIa Study Safety Run-in to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patients with FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment with One Prior Endocrine Therapy (Adjuvant or First-line Metastatic)	7	31/03/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
10/H1306/5	A phase III open multicentre study to investigate the safety and efficacy of BPL's high purity factor X in the treatment of factor X deficient subjects undergoing surgery.	1	31/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0715/77	Phase II trial of cediranib +/-gefitinib for recurrent glioblastoma - DORIC	1	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0190	A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	8	15/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/AL/0322	Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer	2	30/10/2012	Closed - In Follow Up	Y	Study delivered to time and target.

11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders.	2	28/02/2022	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1164	A randomized, open-label, multicenter trial to determine safety and efficacy of Eculizumab in the prevention of Antibody Mediated Rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy (Alexion C10-001 (HCR 1683alx)	2	30/06/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/58	Sub Study to study WN25203,using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1502	A Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2 or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis (post ET-MF) with Splenomegaly.	2	09/12/2015	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1503	A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.	2	12/03/2015	Closed - In Follow Up	Y	Study delivered to time and target.
11/NW/0822	An open-Label, multicenter, multinational study to assess the effect of long-term prolonged-release Fampridine (BIB041) 10mg twice daily on quality of life as reported by subjects with multiple sclerosis	15	01/09/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study delivered to time and target.
12/YH/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/05/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/SC/0372	ChemoCentryx CL005_140 Study	2	01/07/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
12/NE/0342	A multicentre, randomised, double blind, placebo-controlled pivotal study to evaluate the efficacy and safety of GFT505 80mg and GFT505 160mg on steatohepatitis in patients with non-alcoholic steatohepatitis (NASH)	6	01/02/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	6	01/06/2013	Open	Y	Study delivered to time and target.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Treatment with Peginterferon Alfa-2a and Ribavirin	4	21/10/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	01/06/2014	Open	Y	Study delivered to time and target.
10/H0707/93	An open-label positron emission tomography study to investigate and quantify brain and tumour penetration of [11C]lapatinib in subjects with HER2-overexpressing breast cancer	10	01/09/2012	Closed - Follow Up Complete	Y	Study delivered to time and target.

11/LO/1415	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain	4	02/06/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/SC/0499	A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PET-MF).	1	31/08/2013	Closed - In Follow Up	Y	Study delivered to time and target.
08/S0703/171	Effect of liraglutide on body weight in non-dabetic obese subjects or overweight subjects with comorbidities A randomised, double blind, placebo controlled, parrallell group, muli centre, multinational trial with stratification of subject to either one or three years of treatment based on pre diabetes status at randomisation	20	02/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Open	Y	Study delivered to time and target.
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection	5	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to time and target.
08/H1102/0104	ARTemis: Avastin randomised trial with neo-adjuvant chemotherapy for patients with Early Breast Cancer	8	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
08/H0711/45	A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer	10	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/NE/0266	GS-US-334-0133 ? A phase 3 multicenter, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in treatment naïve and treatment experienced subjects with chronic genotype 2 or 3 HCV infection	5	01/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/SC/0161	A randomized, double-blind, placebo controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatment naïve patients	5	01/11/2011	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/H0706/5	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs Placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy	5	01/08/2011	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Open	Y	Study delivered to time and target.
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol A1444042	2	30/04/2014	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1661	Electroanatomical Mapping using Rhythmia System and Catheter	6	01/05/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Naïve Subjects with Chroinc Genotype 1 HCV Infection	5	01/04/2014	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (TURQUOISE II)	4	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.

12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment ?experienced adults with genotype 1 chronic hepatitis C virus (HCV) infection (SAPPHIRE-II)	5	01/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus compared with Telaprevir and Pegasys/Copegus in patients with chronic Hepatitis C genotype 1 virus infection who were prior null responders to treatment with pegylated interferon/ribavirin	5	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	31/12/2013	Open	Y	Study delivered to time and target.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours.	5	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0291	An open label, phase 1 study to evaluate the impact of severe hepatic impairment on the pharmacokinetics and safety of vemurafenib in BRAFV600 mutation-positive cancer patients	10	No Date Agreed With Sponsor	Open	N/A	
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	5	30/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	1	01/08/2014	In set up	N/A	Date agreed to recruit to target not yet passed.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	20	31/01/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	No Date Agreed With Sponsor	Open	N/A	
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)	40	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0501	A phase 2, randomised, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of maribavir versus valganciclovir for treatment of CMV infections in transplant recipients who do not have CMV organ disease	1	31/03/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/NE/0125	PRESTO Neo.1.C/E	15	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTI), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N/A	Date agreed to recruit to target not yet passed.

13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (protocol ID EMR200592-001)	5	01/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma	2	17/08/2018	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4	No Date Agreed With Sponsor	Open	N/A	
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of CastrationResistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	2	30/09/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with compensated cirrhosis secondary to non alcoholic steatohepatitis (NASH)	5	No Date Agreed With Sponsor	Open	N/A	
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with advanced liver fibrosis but not cirrhosis secondary to non alcoholic steatohepatitis (NASH)	5	No Date Agreed With Sponsor	Open	N/A	
12/LO/0720	A Phase 1 Randomised Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis	4	30/06/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)	5	01/02/2015	In set up	N/A	Date agreed to recruit to target not yet passed.
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (iSpot)	8	29/05/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	12	31/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1358	Randomized, Double-Blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC In Patients With Metastatic Colorectal Cancer Refractory To Standard Chemotherapies	5	10/10/2012	Withdrawn	N/A	
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	2	15/04/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/EE/0055	Research Project in Association with Protocol WN25 203 "CSF sample retention for biomarker assay development"	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - Follow Up Complete	N/A	Only patients failing screening from feeder study able to enter. No screen fails occurred.
12/WS/0180	A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy	2	12/03/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naive genotypes 1, 2, 3 or 4 in subjects co-infected with HIV	2	30/04/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0223	A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA) - Protexo Registry	400	No Date Agreed With Sponsor	Suspended	N/A	

08/H0301/127	A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer.	5	No Date Agreed With Sponsor	Closed - Follow Up Complete	N/A	
03/7/029	Does Adjuvant Zoledronic Acid Reduce Recurrence in Patients with High Risk Localised Breast Cancer.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	Study in follow up since 2006.
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200	No Date Agreed With Sponsor	Open	N/A	
07/H1211/171	A Phase 1/2 Study of SKI-606 in Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myeloid or Acute Lymphoblastic Leukaemia, who are Resistant to or Intolerant of Imatinib or Dasatinib	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	Study in follow up since 2009.
11/AL/0120	An open-label, multi-centre, randomized phase III study of S-1 and cisplatin compared with 5-FU and cisplatin in patients with metastatic diffuse gastric cancer previously untreated with chemotherapy	3	06/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
05/MRE09/84	National Cancer Research Institute Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome Trial 16	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - Follow Up Complete	N/A	
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
07/H0605/76	ICON6 - A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of cediranib, in combination with platinum-based chemotherapy and as a single agent maintenance therapy	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	Study in follow up since 2011.
10/H1111/44	A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - Follow Up Complete	N/A	Study in follow up since 2011.
04/MRE11/18	QUASAR 2 Multicentre international study of capecitabine +/- bevacizumab as adjuvant treatment of colon cancer	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	Study in follow up since 2010.
07/H0304/91	A Randomised, 4-arm, placebo-controlled phase 2 trial of AMG 386 in combination with bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in subjects with Her-2-negative, metastatic or locally recurrent breast cancer	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	
13/SC/0146	A phase III, randomised, open label, activecontrolled study of an interferonfree regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylated interferon± and ribavirin in treatment naive patients with chronic genotype 1b Hepatitis C Virus infection	3	30/03/2016	Withdrawn	N/A	Date agreed to recruit to target not yet passed.
13/EE/0276	A Phase 3B Randomized, OpenLabel MultiCenter Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	4	01/01/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Treatment with Erlotinib	12	01/03/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1352	A phase II, open-label, multi-centre, randomised study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with docetaxel in patients with non-small cell lung cancer after platinum failure	2	No Date Agreed With Sponsor	Open	N/A	
11/SC/0358	An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C (Clinical Protocol AI444026)	1	28/02/2014	Closed - In Follow Up	N/A	Date agreed to recruit to target not yet passed.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids and long acting betaagonists	6	01/08/2013	Suspended	N/A	

12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident Cardiovascular Disease	100	01/05/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	15/06/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	In set up	N/A	Date agreed to recruit to target not yet passed.
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (mtx) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (ra) who have demonstrated an inadequate response to prior disease-modifying anti-rheumatic drugs (dmards) treatment and have initiated roactemra? (tocilizumab, tcz) in combination with mtx	5	01/01/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SW/0124	A performance evaluation study of UROSENS(TM) MCM5-ELISA for the detection of prostate cancer in patients with known disease and in those presenting with raised serum prostate-specific antigen and/or abnormal prostate gland morphology	250	No Date Agreed With Sponsor	Open	N/A	
06/MRE06/59	COIN-B A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of metastatic colorectal cancer.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	Study in follow up since 2010.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically In The Breast Or Axillary Lymph Nodes Following Preoperative Therapy	3	01/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0431	A Multi-center, open-label, adaptive, randomised study of Palifosfamide-tris, a novel DNA crosslinker, in combination with Carboplatin and Etoposide (PaCE) chemotherapy versus Carboplatin and Etoposide (CE) alone in chemotherapy naive patients with extensive stage Small Cell Lung Cancer	5	01/04/2014	Withdrawn	N/A	Date agreed to recruit to target not yet passed.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	7	01/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Open	N/A	Date agreed to recruit to target not yet passed.
08/H0803/177	A pragmatic randomised controlled trial of physical activity as an aid to smoking cessation during pregnancy	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	
12/EE/0400	GS-US-334-0109 ? An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	1	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	4	01/01/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/0984	A Randomized, Open-Label Phase 2 Study Of The Ido Inhibitor Incb024360 Versus Tamoxifen For Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma Or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy	5	31/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0629	A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	5	01/06/2014	Suspended	N/A	Date agreed to recruit to target not yet passed.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Longterm Safety and Efficacy of AMG 145	8	01/01/2014	Open	N/A	Date agreed to recruit to target not yet passed.
09/H0505/98	A multicenter, Double-blind, Randomised, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a single treatment of BOTOX(Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a treatment with Botox as applicable in patients with Idiopathic Overactive Bladder with Urinary Incontinence.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	

10/H0713/88	A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia.	350	30/09/2011	Closed - Follow Up Complete	N	
11/H0502/12	An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant treatment setting	20	30/04/2012	Open	N	
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/06/2013	Open	N	
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia	5	01/05/2013	Closed - In Follow Up	N	
12/SC/0435	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) verusu placebo, in co-administration with donepezil (10mg/day) in patients with moderate Alzheimer's Disease	10	01/07/2013	Open	N	
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like moleculae 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Open	N	
12/SS/0028	The Sapheon Closure System (SCS) Kit - European Sapheon Closure System Observational Propective (Escope) Observational Study	70	31/07/2012	Closed - In Follow Up	N	
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/01/2013	Open	N	
11/NW/0690	Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)	8	31/07/2012	Closed - In Follow Up	N	
09/H0406/106	Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL.	5	30/09/2012	Closed - Follow Up Complete	N	
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	5	01/01/2014	Closed - In Follow Up	N	
12/LO/1156	A Phase III , Randomised, Double-blind , Controlled Study of Cabozantinib (XL184) vs Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 -COMET EXELIXIS Study ? COMMET -1	2	No Date Agreed With Sponsor	Closed - Follow Up Complete	N	
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and BT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)	5	01/05/2013	Closed - In Follow Up	N	
11/LO/1023	A 12Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion	10	31/10/2013	Closed - In Follow Up	N	
09/H0707/95	A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension - Grifphon2	5	30/06/2013	Closed - Follow Up Complete	N	
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naïve or Prior Replacers to Alfa/RBV Therapy	4	01/11/2013	Closed - In Follow Up	N	
08/H1010/66	Protocol H3E-MC-JMIG - Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology	5	01/01/2011	Closed - In Follow Up	N	

10/H0717/68	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic Cell Transplants (HCTs).	15	30/11/2011	Closed - In Follow Up	N	Study in follow-up since 2012.
07/H1008/229	A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status	3	31/03/2013	Closed - In Follow Up	N	
12/SC/0042	A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with PegIFN-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFN and ribavirin therapy - TMC435HPC3001 (ATTAIN)	5	30/09/2012	Closed - In Follow Up	N	
12/LO/0268	Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment Experienced Subjects with Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection	4	01/03/2013	Closed - In Follow Up	N	
12/SC/0025	A 24month, phase IIIb, openlabel, randomized, activecontrolled, 3arm, multicenter study assessing the efficacy and safety of an individualized, stabilizationcriteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) - BRIGHTER	7	28/02/2013	Closed - Follow Up Complete	N	
12/SC/0024	A 24month, phase IIIb, openlabel, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) - CRYSTAL	5	31/07/2012	Closed - In Follow Up	N	
12/LO/0410	A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy (BEYOND study)	12	30/11/2012	Closed - Follow Up Complete	N	
11/EM/0305	A Phase 3 Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects with Moderate to Severe Plaque-type Psoriasis (CADMUS)	2	31/10/2013	Closed - Follow Up Complete	N	
10/H0711/6	Cardiovascular outcomes to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type 2 diabetes (T2D)	60	30/05/2011	Closed - Follow Up Complete	N	
10/H1002/27	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)	20	01/11/2012	Closed - In Follow Up	N	
10/H1211/20	LEADER, liraglutide cardiovascular outcome study in type 2 diabetes	20	01/03/2012	Closed - In Follow Up	N	
11/WM/0279	Neural Cardiac Therapy for Heart Failure (NECTAR-HF) Research Study	10	31/12/2013	Closed - In Follow Up	N	
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	8	01/07/2013	Closed - Follow Up Complete	N	
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	19/11/2013	Open	N	
12/LO/0009	Ranolazine in AF following an electrical cardioversion	10	01/08/2012	Closed - Follow Up Complete	N	
13/WA/0064	A performance evaluation study of UROSENS(TM) MCM5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	01/11/2013	Open	N	

13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	6	01/12/2013	Open	N	
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naive Women	10	19/12/2013	Open	N	
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	3	01/12/2013	Open	N	
12/SC/0540	A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in combination with Faldaprevir and Ribavirin in Treatment-Naive Patients with Chronic Genotype 1 HCV Infection	3	No Date Agreed With Sponsor	Closed - Follow Up Complete	N	
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor VIII Variant (813), in adult Hemophilia A and B Subjects with or without inhibitors	1	01/03/2013	Open	N	
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	31/12/2013	Closed - In Follow Up	N	